Pfizer yesterday said it has submitted a supplemental biologics license application for its COVID-19 vaccine, asking that the Food and Drug Administration expand approval to include individuals age 12 to 15. The supplemental application includes longer-term follow-up data from its ongoing phase 3 clinical trial for this age group, which continues to affirm its extremely high efficacy among these patients.

Pfizer also provided an update on its clinical study of the vaccine’s efficacy and safety among children between 6 months and 5 years old. Each dose for that group is three micrograms. As part of the update, Pfizer revealed that it is evaluating the addition of a third dose for the younger group, administered two months after the completion of an initial two-dose regimen. Pfizer also plans to evaluate the 5-12 age group’s response to a third dose of the 10-micogram formulation currently administered to those children.
 

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…